8-K
filed May 25, 2023, 7:59 PM ET
ticker QNCX
CIK 0001662774
other material
confidence high
sentiment neutral
materiality 0.35
Quince Therapeutics shareholders approve 1-for-10 reverse stock split and elect directors at annual meeting
Quince Therapeutics, Inc.
- Shareholders approved 1-for-10 reverse stock split: 22.3M votes for, 4.0M against.
- Margaret McLoughlin and Una Ryan elected as Class I directors with over 8.1M votes each.
- Ratification of BDO USA as auditor for FY2023 approved with 22.9M votes for.
- Advisory vote on executive compensation passed with 8.7M votes for, 2.3M against.
Key facts
Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Quince Therapeutics, Inc. shareholders approved Election of two Class I directors at the 2023-05-24 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-24
Exact text from the filing
The Company’s stockholders approved the election of two Class I directors to the Board of Directors for three year terms or until their respective successors are duly elected and qualified or until their earlier death, resignation, disqualification or removal.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Quince Therapeutics, Inc. shareholders approved Ratification of Selection of Independent Registered Accounting Firm BDO USA, LLP at the 2023-05-24 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-24
Exact text from the filing
The Company’s stockholders ratified the selection of BDO USA, LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Quince Therapeutics, Inc. shareholders approved Advisory approval of the compensation of the Company's named executive officers at the 2023-05-24 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-05-24
Exact text from the filing
The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.99
Quince Therapeutics, Inc. shareholders approved Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split at a ratio of one-for-ten at the 2023-05-24 meeting.
- Proposal
- reverse split
- Outcome
- passed
- Meeting
- 2023-05-24
Exact text from the filing
The Company’s stockholders approved the amendment to the Company’s amended and restated certificate of incorporation to effect a reverse stock split of the issued and outstanding common stock at a ratio of one-for-ten.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.